Switch theme
Sign up to access all valuation multiples
Fukuda Denshi Co Ltd develops and manufactures medical electronic equipment. The firm operates in four segments: physiological diagnostic equipment, patient monitoring equipment, medical treatment equipment, and consumables and other products. The physiological diagnostic equipment business sells electrocardiographs, vascular screening systems, and blood cell counters. The patient monitoring equipment segment sells patient monitors and transmitters. The medical treatment equipment segment contributes the largest proportion of revenue and sells pacemakers and medical equipment for home treatment. The consumables and other products segment sells disposable electrodes and consumables used for the firm’s devices. Fukuda Denshi generates the vast majority of its sales in Japan.
1948
3.8K+
LTM Revenue $940M
LTM EBITDA $243M
$738M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fukuda Denshi has a last 12-month revenue of $940M and a last 12-month EBITDA of $243M.
In the most recent fiscal year, Fukuda Denshi achieved revenue of $933M and an EBITDA of $244M.
Fukuda Denshi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fukuda Denshi valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $895M | $933M | XXX | XXX | XXX |
| Gross Profit | $449M | $468M | XXX | XXX | XXX |
| Gross Margin | 50% | 50% | XXX | XXX | XXX |
| EBITDA | $230M | $244M | XXX | XXX | XXX |
| EBITDA Margin | 26% | 26% | XXX | XXX | XXX |
| Net Profit | $108M | $115M | XXX | XXX | XXX |
| Net Margin | 12% | 12% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Fukuda Denshi's stock price is JPY 6080 (or $40).
Fukuda Denshi has current market cap of JPY 175B (or $1.2B), and EV of JPY 111B (or $738M).
See Fukuda Denshi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $738M | $1.2B | XXX | XXX | XXX | XXX | $3.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Fukuda Denshi has market cap of $1.2B and EV of $738M.
Fukuda Denshi's trades at 0.8x LTM EV/Revenue multiple, and 3.0x LTM EBITDA.
Analysts estimate Fukuda Denshi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Fukuda Denshi and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $738M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 3.0x | XXX | XXX | XXX |
| P/E | 10.0x | XXX | XXX | XXX |
| P/E/Growth | 5.8x | XXX | XXX | XXX |
| EV/FCF | 9.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFukuda Denshi's NTM/LTM revenue growth is 3%
Fukuda Denshi's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Fukuda Denshi's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Fukuda Denshi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Fukuda Denshi and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 29% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 34% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fukuda Denshi acquired XXX companies to date.
Last acquisition by Fukuda Denshi was XXXXXXXX, XXXXX XXXXX XXXXXX . Fukuda Denshi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Fukuda Denshi founded? | Fukuda Denshi was founded in 1948. |
| Where is Fukuda Denshi headquartered? | Fukuda Denshi is headquartered in Japan. |
| How many employees does Fukuda Denshi have? | As of today, Fukuda Denshi has 3.8K+ employees. |
| Is Fukuda Denshi publicy listed? | Yes, Fukuda Denshi is a public company listed on TKS. |
| What is the stock symbol of Fukuda Denshi? | Fukuda Denshi trades under 6960 ticker. |
| When did Fukuda Denshi go public? | Fukuda Denshi went public in 1982. |
| Who are competitors of Fukuda Denshi? | Similar companies to Fukuda Denshi include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Fukuda Denshi? | Fukuda Denshi's current market cap is $1.2B |
| What is the current revenue of Fukuda Denshi? | Fukuda Denshi's last 12-month revenue is $940M. |
| What is the current EBITDA of Fukuda Denshi? | Fukuda Denshi's last 12-month EBITDA is $243M. |
| What is the current EV/Revenue multiple of Fukuda Denshi? | Current revenue multiple of Fukuda Denshi is 0.8x. |
| What is the current EV/EBITDA multiple of Fukuda Denshi? | Current EBITDA multiple of Fukuda Denshi is 3.0x. |
| What is the current revenue growth of Fukuda Denshi? | Fukuda Denshi revenue growth between 2023 and 2024 was 4%. |
| Is Fukuda Denshi profitable? | Yes, Fukuda Denshi is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
